netFormulary Birmingham, Sandwell, Solihull and environs APC Formulary NHS
Maintained by Midlands and Lancashire Commissioning Support Unit  
 Introduction
Birmingham, Sandwell, Solihull and environs Joint Formulary

Useful Links

APC and Other Links

BSSE APC APC Minutes Approved Clinical Guidelines and Position Statements
Rationales for Initiation, Continuation and Discontinuation (RICaDs) Effective Shared Care Agreements  (ESCAs) NICE
New Drug applications
APC decision
BNF MHRA Medicines and Medical devices Safety Update
NHS England DECISION TO DECLINE PRESCRIBING FORM

News Feed

Update (Jan 2017): the Antimicrobial Dressings Guideline for Adults is now published. This guideline must be used in conjunction with the full wound management formulary. Click here for guideline.
Update (Jan 2017): the wound management formulary is now published. Click here
Update (Jan 2017)- Triptorelin s.c. injection (Decapeptyl® SR) has been added to the formulary for advanced prostate cancer. Click here
Formulary UPDATE: new drugs added to the formulary:-
  • Chapter 12 - Azelastine and fluticasone (Dymista®) [Sept 16]
  • Chapter 6 - Dulaglutide (Trulicity® ) [Oct 16]
  • Chapter 2 - Midodrine - (Bramox®) [Nov 16]
  • Chapter 4 - Levetiracetam granules in sachets (Desitrend®) [Dec 16]
  • Chapter 4 - Sodium valproate prolonged release granules in capsules and sachets. (Episenta®) [Dec 16]
  • Chapter 6 - Alendronate 70mg effervescent tablets (Binosto®) [Dec 16]
  • Chapter 3 - Hypertonic sodium chloride (Resp-Ease®) [Dec 16]
  • Chapter 13 - Propantheline bromide for hyperhidrosis [Dec 16]
    Update (Nov 2016): Epiduo gel has been added to the formulary Click here
    Update (Nov 2016): Enstilar cutaneous foam has been added to the formulary Click here

    >>> more news
  • ABOUT THE BIRMINGHAM, SANDWELL, SOLIHULL AND ENVIRONS JOINT FORMULARY

    The Formulary is being developed by the Birmingham, Sandwell, Solihull and environs (BSSE) Area Prescribing Committee (APC) with the aim of promoting safe, evidence-based and cost effective prescribing within the local community.

    It is formatted in accordance with BNF chapter classification for ease of use and includes:

    • Hyperlinks to e-BNFe-BNFc and to the electronic medicines compendium which holds Summaries of Product Characteristics
    • First and Second choices where possible to assist cost-effective prescribing
    • Restricted medicines with approved indications and/or prescriber requirements
    • Links to relevant local and national guidelines






    Please note: patients should not make decisions on their treatment based on comments recorded in meetings but should discuss any concerns with their prescriber. 

    Key to Formulary recommendations

    All drugs included in the Formulary are allocated a traffic light status. The traffic light status offers guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

    Red 
    Initiation and maintenance of prescribing by Specialists only.      
                                                                                                                              
    Amber 
    Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate, or initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist.
          
    Some amber medicines require agreement with the local (internal) medicines committee prior to initiation; others may require a framework to support safe transfer and maintenance of care such as a RICaD or ESCA. The Formulary will be annotated to reflect these requirements. 
    Green 
    Initiation and maintenance of prescribing by Specialists, GPs and other qualified clinicians.      
    Grey 
    Positive NICE TA and /or awaiting local clarification on place in therapy ; Please contact your Medicines Optimisation team for more information.       
    Black 
    Non Formulary; may be prescribed following approval by individual hospital Medicines Management Committees for specific patients.


     The term 'Specialist' refers to Consultants and General Practitioners with a Specialist Interest.


    The BSSE Formulary is not intended to be a static document. Requests for new medicines to be added to the Formulary may be made by Consultants, GPs and other appropriate senior clinicians within the BSSE health community. These are considered in line with the criteria outlined in the application form and based on the identified funding priorities within the health economy.

    The APC will only consider applications which have been via the local approval process and signed by the Chair of the relevant advisory/decision making committee in secondary care. For primary care initiated drugs, applications will be via the CCG Medicines Leads.

    Application forms and further details of the process are available by emailing cmcsu.medicines-management@nhs.net

    This Formulary is currently under construction and will be populated as the BNF chapters are reviewed. Trust formularies should be referred to for chapters that have not been reviewed.

    Representatives from Pharmaceutical Industry wishing to contact the BSSE APC can do so via the APC generic email cmcsu.medicines-management@nhs.net. This does not however guarantee an appointment  for a meeting or telephone call. 

    Below are website links to BSSE APC member CCGs and Trusts. Links to Trust Formularies are also included.

    CCG links

    NHS Birmingham CrossCity Clinical Commissioning Group NHS Birmingham South Central Clinical Commissioning Group NHS Sandwell and West Birmingham Clinical Commissioning Group
    NHS Solihull Clinical Commissioning Group NHS South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group  

    Trust links

    Birmingham and Solihull Mental Health NHS Foundation Trust
    Formulary
    Birmingham Children’s NHS Foundation Trust
    Formulary
    Birmingham Community Healthcare
    Formulary
    Birmingham Women’s NHS Foundation Trust
    Formulary
    The Royal Orthopaedic Hospital NHS Foundation Trust  

    Copyright notice

    The copyright protected material on this site may be reproduced free of charge in any format or medium. This is subject to the material being reproduced accurately and not used in a misleading context. References to and quotations of prescribing recommendations must faithfully reflect the meaning intended by the Committee. The wording used must be unambiguous and match fully and precisely with the context and content of the original recommendation. The source of any reference or quotation must be identified and wherever reasonably practicable supplied in its original form




    NetFormulary
       Visits = 93065